Laura Armengou‐Garcia

Laura Armengou‐Garcia

Auto-generated profile, based on publicly available information

Laura Armengou‐Garcia

Division of Neurology, Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2024 in Movement Disorders
Verified
Journal Article
Open access
LALaura Armengou‐Garcia
Laura Armengou‐Garcia
CSCarlos A. Sanchez‐Catasus
Carlos A. Sanchez‐Catasus
IAICIAR AVILES-OLMOS
ICIAR AVILES-OLMOS
AJAdolfo Jiménez‐Huete
Adolfo Jiménez‐Huete
GMGenoveva Montoya‐Murillo
Genoveva Montoya‐Murillo
MRMaría Cruz Rodríguez-Oroz
María Cruz Rodríguez-Oroz
Background: Unilateral subthalamic nucleus (STN) ablation using magnetic resonance–guided focused ultrasound (MRgFUS) is being explored as a new treatment for asymmetric Parkinson's disease (PD).Objectives: The aims were to study the efficacy and safety of this treatment in asymmetric PD patients and to characterize the lesions.Methods: This prospective, single‐center, open‐label study evaluated asymmetric PD patients at 6 (n = 20) and 12 months (n = 12) after MRgFUS lesion of the STN. The primary outcome was the change in the Movement Disorders Society‐Unified Parkinson's Disease Rating Scale, Part III (MDS‐UPDRS III), score in off medication on the treated side and the adverse events (AEs) at 6‐month follow‐up. We also evaluated cognitive–neuropsychological changes, self‐assessment of clinical improvement, and the correlation of the lesion volume with the motor outcomes.Results: On the treated side, the MDS‐UPDRS III score (mean difference = 13.8) and the scores in rigidity, bradykinesia, and tremor improved (P < 0.001) throughout the follow‐up compared to baseline (at 6 months: rigidity mean difference = 2.8, improvement: 83.5%; bradykinesia mean difference = 6.0, improvement: 69.4%; tremor mean difference = 4.7, improvement: 91.5%). One patient had severe weakness in the treated hemibody, 1 had moderate dyskinesia, and 1 was in moderate confusional state that became mild (weakness) or completely resolved (dyskinesia and confusional state) at 6 months. The rest of the AEs were mild. We observed no clinically relevant changes in cognitive–neuropsychological tests. The percentage of ablation of the STN correlated with the improvement in the total MDS‐UPDRS III and contralateral tremor scores (P < 0.05).Conclusion: Unilateral MRgFUS lesion of the STN resulted in a significant motor improvement. We observed no persistent severe AEs, although mild, mostly transient AEs were frequent. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

8 August 2016 in Journal of Raman Spectroscopy
Verified
Journal Article
Closed access
PDF file
MVM. Veneranda
M. Veneranda
JAJulene Aramendia
Julene Aramendia
OGOlivia Gomez-Laserna
Olivia Gomez-Laserna
SVS. Fdez‐Ortiz de Vallejuelo
S. Fdez‐Ortiz de Vallejuelo
LGL. Garcia
L. Garcia
JMJuan Manuel Madariaga
Juan Manuel Madariaga

19 December 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
HRHeidi C. Riek
Heidi C. Riek
NVNaomi P. Visanji
Naomi P. Visanji
IPIsabell C. Pitigoi
Isabell C. Pitigoi
DLDaniel G. Di Luca
Daniel G. Di Luca
LALaura Armengou-Garcia
Laura Armengou-Garcia
DMDouglas P. Munoz
Douglas P. Munoz
Oculomotor behaviour changes in patients with Parkinson’s disease (PD) are a promising source of prodromal disease markers. Capitalizing on this phenomenon to facilitate early diagnosis requires oculomotor assessment in prodromal cohorts. We examined oculomotor behaviour in non-manifesting LRRK2 G2019S mutation carriers (LRRK2-NM), who have heightened PD risk. Seventeen LRRK2-NM participants, 47 patients with idiopathic PD, and 63 healthy age-matched control participants completed an interleaved pro- and antisaccade task while undergoing video-based eye-tracking. We analyzed between-group differences in saccade, pupil, blink, and fixation acquisition behaviour. Patients with PD showed previously demonstrated abnormalities (saccade hypometria, antisaccade errors). Relative to controls, LRRK2-NM participants and patients with PD both displayed increased short-latency prosaccades and reduced pupil velocity, plus altered fixation acquisition—less preemptive returning of gaze to the future fixation point location. Interestingly, the effect on blink probability was opposite—higher than controls in LRRK2-NM participants but lower in patients with PD. Future longitudinal studies must confirm the viability of these features as prodromal PD markers.

16 June 2025 in Expert Opinion on Emerging Drugs
Verified
Journal Article
Closed access
PGPriti Gros
Priti Gros
LGLaura Armengou Garcia
Laura Armengou Garcia
SFSusan H. Fox
Susan H. Fox
The symptomatic treatment of Parkinson Disease (PD) relies on levodopa. With disease progression, the response to levodopa becomes variable, leading to fluctuations in benefit on PD symptoms. These motor fluctuations are challenging to manage and negatively impact quality of life in PD. We provide a review of experimental, non-approved pharmacological therapies in phase II and III clinical trials from 2018 to 2024 for PD motor fluctuations. New formulations of levodopa to improve bioavailability are in development. These include another subcutaneous infusion with efficacy in reducing motor fluctuations and an intranasal delivery with tolerability reported. An oromucosal formulation of apomorphine was safe, further studies are needed. Preliminary results of a phase III study of dopamine D1/D5 agonist tavapadon and phase II of CVN424, a GRP6 inverse agonist suggest improved ON time. Negative studies were reported with foliglurax (MGluR4 inverse agonist) and the repurposed drugs naftazone and bumetanide. Several novel targets are in early-stage development with results awaited. Overall, it is unclear whether the field is significantly further ahead, as the benefit of these emerging drugs in comparison with currently available agents for motor fluctuations needs to be clarified.

19 December 2025 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
NBNathaniel Bendahan
Nathaniel Bendahan
LALaura Armengou‐Garcia
Laura Armengou‐Garcia
MMMia Mojica
Mia Mojica
RLRiccardo Ludovichetti
Riccardo Ludovichetti
TRTaryn J. Rohringer
Taryn J. Rohringer
PAPaula Alcaide‐Leon
Paula Alcaide‐Leon